25 employees
Revolo Biotherapeutics has developed therapies that achieve superior long-term disease remission from less frequent chronic dosing.
2011
$52M
from 3 investors over 3 rounds
Revolo Biotherapeutics raised $52M on September 21, 2020
Investors: Metellus AG, 24Haymarket and Morningside Venture Capital 晨兴资本